SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Association between cancer cachexia and treatment-related adverse outcomes in patients with gastrointestinal cancers: a systematic review and meta-analysis.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCachexia represents a critical nutritional problem, especially among patients with gastrointestinal cancer, and is potentially linked to unfavorable outcomes. Nevertheless, the influence of cancer cachexia on treatment-related adverse events in these patients remains insufficiently incorporated into current understanding. This systematic review and meta-analysis investigated the association between cancer cachexia and treatment-related adverse outcomes in patients with gastrointestinal cancers.
methodsFive electronic databases were searched for relevant studies. Cohort studies investigating the association of cachexia with postoperative complications, chemotherapy-related adverse events, radiotherapy-related adverse events, length of hospital stay, and readmission in patients with gastrointestinal cancers were included.
resultsThirty-four studies involving 27,473 participants were included. Cancer cachexia was significantly associated with higher odds of postoperative complications (odds ratio [OR] 1.38, 95% confidence interval [CI] = 1.11-1.72) and prolonged length of hospital stay (mean difference = 2.09, 95% CI = 0.91-3.26). No significant association was observed between cancer cachexia and chemotherapy-related adverse events (OR = 1.42, 95% CI = 0.57-3.54). All pooled analyses showed considerable to substantial heterogeneity. No studies evaluating radiotherapy-related adverse events and only one study evaluating readmission met the inclusion criteria; therefore, these outcomes could not be quantitatively synthesized.
conclusionsCancer cachexia was associated with an increased risk of postoperative complications and prolonged length of hospital stay in patients with gastrointestinal cancers. However, because of the substantial heterogeneity and the very low certainty of the evidence, these findings should be interpreted with caution and cannot be considered definitive.
Indexed as
Identifiers
42909685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.